Brian Van Tine, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Aadi
    Date added:
    06/11/2024
    Date updated:
    06/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Hinge Bio
    Date added:
    06/11/2024
    Date updated:
    06/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Kronos Bio
    Date added:
    06/11/2024
    Date updated:
    06/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Kronos Bio
    Topic:
    Speaker/Travel
    Date added:
    06/11/2024
    Date updated:
    06/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Total Health Conference
    Topic:
    Speaker/Travel
    Date added:
    06/11/2024
    Date updated:
    06/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Oncology Education
    Topic:
    Speaker/Travel
    Date added:
    06/11/2024
    Date updated:
    06/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Travel
    Ineligible company:
    Adaptimmune
    Date added:
    06/11/2024
    Date updated:
    06/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Travel
    Ineligible company:
    Polaris
    Date added:
    06/11/2024
    Date updated:
    06/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Boehringer Ingelheim
    Topic:
    Ad Board Meeting
    Date added:
    06/11/2024
    Date updated:
    06/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    PTC Therapuetics
    Topic:
    Ad Board Meeting
    Date added:
    06/11/2024
    Date updated:
    06/20/2024

Pages

Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology